Your session is about to expire
← Back to Search
Other
OHR/AVR118 for Cancer Cachexia
Phase 2
Waitlist Available
Led By Martin Chasen, MBChB
Research Sponsored by Ohr Pharmaceutical Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks
Awards & highlights
Study Summary
The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life. Based on a previous study in patients with AIDS, possible benefits may include improved appetite and strength; weight gain, improved mood; and decreased fatigue.
Eligible Conditions
- Cancer Cachexia
- Anorexia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ four weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Alleviation of multiple cachexia symptoms
Secondary outcome measures
Corticotropin
Trial Design
1Treatment groups
Experimental Treatment
Group I: OHR/AVR118Experimental Treatment1 Intervention
Experimental Drug
Find a Location
Who is running the clinical trial?
Ohr Pharmaceutical Inc.Lead Sponsor
5 Previous Clinical Trials
392 Total Patients Enrolled
Martin Chasen, MBChBPrincipal InvestigatorOttawa Hospital Cancer Centre
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger